LENSAR says the system is now FDA cleared for all the critical components of laser cataract surgery including lens fragmentation, anterior capsulotomy (with or without phacofragmentation) and corneal incisions.
“We are pleased with this latest broadening of the cleared indications for the LENSAR system as it demonstrates the continued ability of the LENSAR team to establish strategic development and commercialization objectives and then systematically deliver on those goals,” said Nick Curtis, LENSAR’s CEO, in the release. “At the same time, the continued expansion of FDA-cleared indications provides significant value to the cataract surgeon community and we expect this important regulatory milestone to add to the steadily increasing demand for our system worldwide.”
LENSAR is headquartered in Orlando, Fla.
Related Articles on FDA Clearances:
Ethicon Receives FDA Clearance for Sealant Patch
Devicor Receives FDA Clearance for Biopsy System
IRIDEX Receives FDA Clearance for New Laser Delivery System
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.